Chris Rinsch is co-founder and CEO of Amazentis. For more than two decades, he has been an innovator in the life sciences arena. Before founding Amazentis in 2007, Rinsch worked in venture capital investing in pioneering life sciences companies in the nutrition space and in biotechnology developing cell-based therapies at the Swiss biotech company ISOTIS SA, formerly Modex SA. Rinsch has authored original publications in leading scientific journals, including Nature Medicine, Nature Metabolism, Jama Open, Cell Reports Medicine and others, for his research on Urolithin A, mitochondrial health, muscle function, and joint health. He is also an inventor on several internationally filed and granted patents.

Rinsch holds an MBA from INSEAD, France, a PhD in Cell and Molecular Biology from the University of Lausanne, a Master of Science in Biomedical Engineering from U.T. Southwestern Medical Center, and a Bachelor of Science in Engineering from Harvey Mudd College.